We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » APIC Advises API Distributors on Good Distribution Practices

APIC Advises API Distributors on Good Distribution Practices

June 6, 2014

Distributors of active pharmaceutical ingredients in Europe should build quality management systems that include the same features as drugmakers’ QMS in areas such as contamination control and documentation, according to a new reference guide on good distribution practices.

The guide from the Brussels-based Active Pharmaceutical Ingredients Committee (APIC) includes calls for distributors’ facilities to be designed to minimize contamination risks by complementing the flow of personnel and materials. Facilities should include defined areas for receipt, identification, sampling and quarantine of incoming products. The buildings also should have appropriate ventilation, air filtration and exhaust systems that control humidity, air pressure, dust and temperature, especially in areas where APIs are exposed.

Staff should ensure all instruments are accurately calibrated, APIC said, with certificates maintained and records open to operating personnel. Ensuring equipment cleanliness should be done by testing the final rinse after cleaning residue or by testing each batch for residue of previous products handled with the same equipment, among other things.

For labeling APIs, the guideline recommends following the World Health Organization’s recommendations requiring the name of the pharmaceutical starting material, the grade and pharmacopeias, international non-proprietary names, amount, batch numbers, retest or expiry dates, storage conditions and handling precautions and identification of manufacturing sites, along with contact information.

Managers should keep records of all procedures and conduct internal audits at least every year, the guide says.

The focus on API compliance is crucial as drugmakers operating in the EU are required to use only active substances distributed in accordance with the Falsified Medicines Directive.

Make sure your distribution chain will protect the integrity of your products, purchase Creating a Master Plan for Drug Warehousing, Transportation and Distribution today!

Pharmaceuticals GMPs

Upcoming Events

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

  • 10Aug

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

  • FDA Warns Baby Neck Floats Used in Water Therapy Can Cause Death or Injury

  • U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing